Vogliviga GM 0.3/80 Tablet contains Voglibose 0.3mg, Metformin 500mg, and Gliclazide 80mg, providing a powerful triple-action therapy for type-2 diabetes mellitus. This formulation targets multiple mechanisms to maintain optimal glycemic control, supporting both fasting and postprandial blood sugar management.
Voglibose delays carbohydrate absorption in the gut, Metformin enhances insulin sensitivity and decreases hepatic glucose output, and Gliclazide stimulates pancreatic insulin secretion. Together, these actions provide comprehensive blood glucose regulation and metabolic stability.
This triple-combination tablet is particularly suitable for patients who are inadequately controlled on dual therapy or monotherapy, offering a convenient, safe, and effective oral dosage. It is widely used in outpatient clinics, hospital settings, and diabetes management programs.
Adding Vogliviga GM 0.3/80 Tablet to your diabetes and metabolic-care portfolio strengthens your offerings, opening opportunities in retail pharmacy distribution, hospital supply, institutional procurement, export markets, and third-party manufacturing. Its strong clinical relevance ensures continuous demand and profitable performance.